Standard chemotherapy provides higher survival rate than experimental in lung cancer patients

Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Read the whole article on Science Daily

More from Science Daily